BeOne Medicines Ltd
57 hedge funds and large institutions have $918M invested in BeOne Medicines Ltd in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 9 closing their positions.
208% more capital inflows, than outflows
Capital inflows: $166M | Capital outflows: $53.9M
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2.73% more ownership
Funds ownership: 17.19% → 19.92% (+2.7%)
2% more funds holding
Funds holding: 56 → 57 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$92.8M |
| 2 |
OppenheimerFunds
New York
|
+$26M |
| 3 |
OrbiMed
New York
|
+$15.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$6.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$9.85M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
-$8.79M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$6.35M |
| 4 |
QF
QVT Financial
New York
|
-$6.22M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.12M |
ONC Hedge Fund Activity: Q2 2017 in Review
57 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q2 2017, worth a combined $918M — up 42% from $645M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ONC positions and 9 closed out — a net gain of 1 holder — while 24 added to existing stakes and 17 trimmed.
The largest buyer was Hillhouse Investment Management, adding an estimated $92.8M. The largest seller was Boxer Capital, cutting an estimated $9.85M.
- 57 institutional investors held BeOne Medicines Ltd (ONC) as of Q2 2017, up from 56 in Q1 2017.
- Funds reported $918M of BeOne Medicines Ltd stock for Q2 2017, up 42% quarter-over-quarter.
- 10 funds opened new BeOne Medicines Ltd positions in Q2 2017 and 9 closed out, a net change of +1 holder.
- The largest BeOne Medicines Ltd buyer in Q2 2017 was Hillhouse Investment Management, an estimated $92.8M added.
- The largest BeOne Medicines Ltd seller in Q2 2017 was Boxer Capital, an estimated $9.85M sold.
Based on aggregated 13F filings for Q2 2017.